[在科特迪瓦(1985-1987)研究伊维菌素(Mectizan)对人盘尾丝虫病的疗效和耐受性。2根据大规模运动对每年或半年给予100、150或200微克/千克单次口服剂量的效果进行评估。

M Larivière, B Beauvais, M Aziz, J F Garin, J Abeloos, F Derouin, M Bamba, M Ferly-Therizol, C Sarfati, D Basset
{"title":"[在科特迪瓦(1985-1987)研究伊维菌素(Mectizan)对人盘尾丝虫病的疗效和耐受性。2根据大规模运动对每年或半年给予100、150或200微克/千克单次口服剂量的效果进行评估。","authors":"M Larivière,&nbsp;B Beauvais,&nbsp;M Aziz,&nbsp;J F Garin,&nbsp;J Abeloos,&nbsp;F Derouin,&nbsp;M Bamba,&nbsp;M Ferly-Therizol,&nbsp;C Sarfati,&nbsp;D Basset","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>One hundred and twenty patients out of 220 in a previous study were retreated after 6 months or one year with doses of 100, 150 or 200 mcg/kg of ivermectin. The tolerance was excellent due probably to the small number of skin microfilariae obtained with the first treatment. The annual treatment with 150 to 200 mcg/kg, better than with 100 mcg/kg, keeps for the year following the second treatment the microfilariae number between 6 and 11% of the initial level. The half-yearly administration keeps it between 1 and 7% and especially 94 to 100% of these retreated patients have a level of microfilariae less than 5 mf/mg. The results obtained with the half-yearly treatment show a considerable reduction of the number of microfilariae in the anterior chamber of the eye and the percentage of positive patients. Ivermectin is a very efficient microfilaricidal drug for the treatment of onchocerciasis and the prevention of ocular complications. Its rational use in mass campaigns should reduce, if not interrupt, the transmission of this parasitic disease.</p>","PeriodicalId":9297,"journal":{"name":"Bulletin de la Societe de pathologie exotique et de ses filiales","volume":"82 1","pages":"48-57"},"PeriodicalIF":0.0000,"publicationDate":"1989-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[A study in the Ivory Coast (1985-1987) of the efficacy and tolerance of ivermectin (Mectizan) in human onchocerciasis. II. Evaluation in the light of mass campaigns on the effect of yearly or half-yearly administration of single oral doses of 100, 150 or 200 mcg/kg].\",\"authors\":\"M Larivière,&nbsp;B Beauvais,&nbsp;M Aziz,&nbsp;J F Garin,&nbsp;J Abeloos,&nbsp;F Derouin,&nbsp;M Bamba,&nbsp;M Ferly-Therizol,&nbsp;C Sarfati,&nbsp;D Basset\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>One hundred and twenty patients out of 220 in a previous study were retreated after 6 months or one year with doses of 100, 150 or 200 mcg/kg of ivermectin. The tolerance was excellent due probably to the small number of skin microfilariae obtained with the first treatment. The annual treatment with 150 to 200 mcg/kg, better than with 100 mcg/kg, keeps for the year following the second treatment the microfilariae number between 6 and 11% of the initial level. The half-yearly administration keeps it between 1 and 7% and especially 94 to 100% of these retreated patients have a level of microfilariae less than 5 mf/mg. The results obtained with the half-yearly treatment show a considerable reduction of the number of microfilariae in the anterior chamber of the eye and the percentage of positive patients. Ivermectin is a very efficient microfilaricidal drug for the treatment of onchocerciasis and the prevention of ocular complications. Its rational use in mass campaigns should reduce, if not interrupt, the transmission of this parasitic disease.</p>\",\"PeriodicalId\":9297,\"journal\":{\"name\":\"Bulletin de la Societe de pathologie exotique et de ses filiales\",\"volume\":\"82 1\",\"pages\":\"48-57\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1989-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bulletin de la Societe de pathologie exotique et de ses filiales\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin de la Societe de pathologie exotique et de ses filiales","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

在之前的一项研究中,220名患者中有120名在6个月或1年后服用100,150或200mcg /kg的伊维菌素治疗。耐受性很好,可能是由于第一次处理获得的皮肤微丝蚴数量很少。150 ~ 200 mcg/kg的年处理比100 mcg/kg的处理效果好,第二次处理后一年微丝蚴数保持在初始水平的6% ~ 11%。半年给药使其保持在1% ~ 7%之间,特别是94% ~ 100%的复诊患者微丝蚴水平低于5 mf/mg。半年治疗的结果显示,眼前房微丝蚴的数量和阳性患者的百分比显著减少。伊维菌素是一种非常有效的治疗盘尾丝虫病和预防眼部并发症的微丝虫病药物。在大规模运动中合理使用疫苗,即使不能阻断这种寄生虫病的传播,也应减少这种疾病的传播。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[A study in the Ivory Coast (1985-1987) of the efficacy and tolerance of ivermectin (Mectizan) in human onchocerciasis. II. Evaluation in the light of mass campaigns on the effect of yearly or half-yearly administration of single oral doses of 100, 150 or 200 mcg/kg].

One hundred and twenty patients out of 220 in a previous study were retreated after 6 months or one year with doses of 100, 150 or 200 mcg/kg of ivermectin. The tolerance was excellent due probably to the small number of skin microfilariae obtained with the first treatment. The annual treatment with 150 to 200 mcg/kg, better than with 100 mcg/kg, keeps for the year following the second treatment the microfilariae number between 6 and 11% of the initial level. The half-yearly administration keeps it between 1 and 7% and especially 94 to 100% of these retreated patients have a level of microfilariae less than 5 mf/mg. The results obtained with the half-yearly treatment show a considerable reduction of the number of microfilariae in the anterior chamber of the eye and the percentage of positive patients. Ivermectin is a very efficient microfilaricidal drug for the treatment of onchocerciasis and the prevention of ocular complications. Its rational use in mass campaigns should reduce, if not interrupt, the transmission of this parasitic disease.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
[Chagas disease]. [Skin manifestations of bilharziasis. Apropos of 24 case reports in Mali]. [Serological evaluation of an antimeningococcal mass vaccination campaign in Niger]. [Echographic study of the morbidity due to urinary bilharziasis in a hyperendemic village in Niger]. [Emergence of strains of Neisseria gonorrhoeae spectinomycin- resistant in Libreville (Gabon): 1st case].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1